Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 797

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 797
---
  A reconciliation of the income tax provision (benefit) by applying the statutory United States federal income tax rate to income (loss) before income taxes is as follows: Rate Reconciliation For the Years EndedDecember 31,     2024    2023   Expected tax at statutory rates $(2,416,700 )  21% $(2,099,400 )  21%Permanent Differences $(157,900 )  1%  (83,000 )  1%State Income Tax, Net of Federal benefit $(822,500 )  7%  (448,100 )  4%State Rate Change-Federal Impact $(42,300)  0%  -   0%State Rate Change Adjustment $201,300   -2%  -   0%Foreign taxes at rate different than US Taxes $(58,900 )  1%  (33,800 )  0%Current Year Change in Valuation Allowance $3,411,100   -30%  2,630,700   -26%Prior Year True-Ups $(114,100)  1%  33,600   0%Income tax provision (benefit) $-   0% $-   0% Deferred tax assets and liabilities are provided for significant income and expense items recognized in different years for tax and financial reporting purposes. Temporary differences, which give rise to a net deferred tax asset is as follows: Deferred Tax Assets/(Liabilities) Detail For the Years Ended December 31,   2024  2023 Deferred Tax Assets (Liabilities):      Stock Based Compensation $1,546,400   1,406,400 Accrued Bonus $17,100   63,300 Accrued Expenses $36,000   - Depreciation $900   (7,800 ROU (Asset) $(148,800)  (92,600)ROU Liability $150,400   95,700 Capitalized R&D $1,967,800   1,960,100 R&D Credit $29,800   29,800 Net Operating Losses (US) $19,647,500   16,665,000